Glioblastoma remains essentially incurable, and new therapeutic approaches are urgently needed. Now, the findings of three serial tissue-based studies suggest that immune-checkpoint inhibition can modify the glioblastoma microenvironment. Following these encouraging observations, the results of two phase III trials of immune-checkpoint inhibition in newly diagnosed glioblastoma, with larger cohorts of patients, are eagerly anticipated.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Circulating biomarkers in patients with glioblastoma
British Journal of Cancer Open Access 31 October 2019
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Weller, M. et al. Glioma. Nat. Rev. Dis. Primers 1, 15017 (2015).
Weller, M. et al. EANO guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 18, e315–e329 (2017).
Weller, M. et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): results of a randomized, double-blind, international phase 3 trial. Lancet Oncol. 18, 1373–1385 (2017).
Reardon, D. A. et al. Randomized phase 3 study evaluating the efficacy and safety of nivolumab versus bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neuro Oncol. 19, iii21 (2017).
Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812–830 (2018).
Zhao, J. et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat. Med. https://doi.org/10.1038/s41591-019-0349-y (2019).
Schalper, K. A. et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat. Med. https://doi.org/10.1038/s41591-018-0339-5 (2019).
Cloughesy, T. F. et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. https://doi.org/10.1038/s41591-018-0337-7 (2019).
Weller, M. Where does O6-methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma? Cancer 124, 1316–1318 (2018).
Weiss, T. et al. NKG2D-dependent anti-tumor effects of chemotherapy and radiotherapy against glioblastoma. Clin. Cancer Res. 24, 882–895 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.W. has received research grants from Abbvie, Adastra, Dracen, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, OGD2, Piqur and Roche and honoraria for lectures, participation in advisory boards and/or consultancy from Abbvie, Basilea, Bristol-Myers Squibb, Celgene, MSD, Merck (EMD), Novocure, Orbus, Roche and Tocagen. E.L.R. has received research grants Amgen, Mundipharma; honoraria for lectures or participation in advisory boards for Abbvie, Daiichi-Sankyo and Novartis.
Rights and permissions
About this article
Cite this article
Weller, M., Le Rhun, E. Immunotherapy for glioblastoma: quo vadis?. Nat Rev Clin Oncol 16, 405–406 (2019). https://doi.org/10.1038/s41571-019-0195-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-019-0195-3
This article is cited by
-
Advances in local therapy for glioblastoma — taking the fight to the tumour
Nature Reviews Neurology (2022)
-
The immune landscape of common CNS malignancies: implications for immunotherapy
Nature Reviews Clinical Oncology (2021)
-
Circulating biomarkers in patients with glioblastoma
British Journal of Cancer (2020)
-
The Prognostic Value of EMT in Glioma and its Role in the Glioma Immune Microenvironment
Journal of Molecular Neuroscience (2020)
-
Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma?
Neurochemical Research (2019)